- Conditions
- Influenza
- Interventions
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 203
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
- Interventions
- Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
- Drug · Behavioral · Other
- Lead sponsor
- Brian Anderson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumor, Adult
- Interventions
- Neoantigen DNA Vaccine, Integrated electroporation device
- Biological · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Influenza
- Interventions
- Inactivated H1N1 Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more
- Conditions
- Premature Birth
- Interventions
- Betamethasone - ACTIVE, Normal Saline - PLACEBO
- Drug · Other
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more
- Conditions
- COVID-19
- Interventions
- Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Standard of Care
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 104
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2008
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
- Conditions
- Syphilis
- Interventions
- Benzathine Penicillin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more
- Conditions
- Influenza
- Interventions
- Influenza Vaccination
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 6 Months to 59 Months
- Enrollment
- 156 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- Entolimod, Placebo, Influenza vaccine
- Drug
- Lead sponsor
- Robert J. Pignolo
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Infertility, Recurrent Miscarriage
- Interventions
- Influenza Vaccine, Sterile Saline
- Biological · Other
- Lead sponsor
- Center for Human Reproduction
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Influenza
- Interventions
- Fluarix, Fluzone
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
- Conditions
- Syphilis, Early Syphilis
- Interventions
- Cefixime 400 milligram Oral Capsule [Suprax], Benzathine Penicillin G
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Los Angeles, California • Oakland, California + 3 more
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster Vaccine GSK1437173A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 8,687 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 37
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Influenza
- Interventions
- AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Smallpox
- Interventions
- Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 32 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Interventions
- Personalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws
- Biological · Device · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • St Louis, Missouri
- Conditions
- Ricin Poisoning
- Interventions
- RVEc
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Fort Deterick, Maryland
- Conditions
- Hot Flashes
- Interventions
- medroxyprogesterone, venlafaxine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 19 more
- Conditions
- Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
- Interventions
- Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
- Conditions
- Breast Cancer
- Interventions
- Sapanisertib, Fulvestrant, Exemestane
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more